Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Sung Bin An 1 Article
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients
Mi-Sook Lee, Eun Ah Jung, Sung Bin An, Yu Jin Kim, Doo-Yi Oh, Ji-Young Song, Sang-Won Um, Joungho Han, Yoon-La Choi
Cancer Res Treat. 2017;49(4):1065-1076.   Published online January 25, 2017
DOI: https://doi.org/10.4143/crt.2016.347
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The discoidin domain-containing receptor tyrosine kinase 2 (DDR2) is known to contain mutations in a small subset of patients with squamous cell carcinomas (SCC) of the lung. Studying the DDR2 mutations in patients with SCC of the lung would advance our understanding and guide the development of therapeutic strategies against lung cancer.
Materials and Methods
We selected 100 samples through a preliminary genetic screen, including specimens from biopsies and surgical resection, and confirmed SCC by histologic examination. DDR2 mutations on exons 6, 15, 16, and 18 were analyzed by Sanger sequencing of formalin-fixed, paraffin-embedded tissue samples. The functional effects of novel DDR2 mutants were confirmed by in vitro assays.
Results
We identified novel somatic mutations of DDR2 in two of the 100 SCC samples studied. One mutation was c.1745T>A (p.V582E) and the other was c.1784T>C (p.L595P), and both were on exon 15. Both patients were smokers and EGFR/KRAS/ALK-triple negative. The expression of the mutant DDR2 induced activation of DDR2 by the collagen ligand and caused enhanced cell growth and tumor progression. Moreover, dasatinib, a DDR2 inhibitor, showed potential efficacy against DDR2 L595P mutant–bearing cells.
Conclusion
Our results suggest that a mutation in DDR2 occurs naturally with a frequency of about 2% in Korean lung SCC patients. In addition, we showed that each of the novel DDR2 mutations were located in a kinase domain and induced an increase in cell proliferation rate.

Citations

Citations to this article as recorded by  
  • Potentially functional variants of PARK7 and DDR2 in ferroptosis‐related genes predict survival of non‐small cell lung cancer patients
    Huilin Wang, Hongliang Liu, Xiaozhun Tang, Guojun Lu, Sheng Luo, Mulong Du, David C. Christiani, Qingyi Wei
    International Journal of Cancer.2024;[Epub]     CrossRef
  • Discoidin Domain Receptor 2: A New Target in Cancer
    Xiaoxiao Xu, Tong Yu, Zhenxing Wang
    Oncology Research and Treatment.2022; 45(4): 205.     CrossRef
  • Unearthing novel fusions as therapeutic targets in solid tumors using targeted RNA sequencing
    Sungbin An, Hyun Hee Koh, Eun Sol Chang, Juyoung Choi, Ji-Young Song, Mi-Sook Lee, Yoon-La Choi
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Squamous cell lung cancer: Current landscape and future therapeutic options
    Sally C.M. Lau, Yuanwang Pan, Vamsidhar Velcheti, Kwok Kin Wong
    Cancer Cell.2022; 40(11): 1279.     CrossRef
  • Complex roles of discoidin domain receptor tyrosine kinases in cancer
    V. Mehta, H. Chander, A. Munshi
    Clinical and Translational Oncology.2021; 23(8): 1497.     CrossRef
  • The Yin and Yang of Discoidin Domain Receptors (DDRs): Implications in Tumor Growth and Metastasis Development
    Sandra Majo, Patrick Auguste
    Cancers.2021; 13(7): 1725.     CrossRef
  • Mutational Landscape of DDR2 Gene in Lung Squamous Cell Carcinoma Using Next-generation Sequencing
    Charles Ricordel, Alexandra Lespagnol, Francisco Llamas-Gutierrez, Marie de Tayrac, Mallorie Kerjouan, Alice Fievet, Houda Hamdi-Rozé, Amyrat Aliouat, Benoit Desrues, Jean Mosser, Hervé Léna
    Clinical Lung Cancer.2018; 19(2): 163.     CrossRef
  • Extracellular matrix functions in lung cancer
    Martin Götte, Ilona Kovalszky
    Matrix Biology.2018; 73: 105.     CrossRef
  • Subjecting appropriate lung adenocarcinoma samples to next‐generation sequencing‐based molecular testing: challenges and possible solutions
    Weihua Li, Tian Qiu, Yun Ling, Shugeng Gao, Jianming Ying
    Molecular Oncology.2018; 12(5): 677.     CrossRef
  • Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
    Ugo Testa, Germana Castelli, Elvira Pelosi
    Cancers.2018; 10(8): 248.     CrossRef
  • Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients
    Zahra Fathi, Seyed Ali Javad Mousavi, Raheleh Roudi, Farideh Ghazi, Sumitra Deb
    PLOS ONE.2018; 13(7): e0200633.     CrossRef
  • 10,147 View
  • 249 Download
  • 14 Web of Science
  • 11 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP